Brief: Firebrick Pharma Says Nasodine COVID-19 Patent Accepted In Europe
13/08/2025 02:43
Aug 13 (Reuters) - Firebrick Pharma Ltd FRE.AX: NASODINE COVID-19 PATENT ACCEPTED IN EUROPE Further company coverage: FRE.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement